Melbourne, May 5, 2026, 08:01 AEST
CSL Limited (CSL.AX) snapped up another 54,887 ordinary shares on May 1, according to a Monday filing. That brings the tally to 6.41 million shares under its ongoing buyback. The biotech firm dropped A$6.86 million on the latest batch, with its on-market repurchase still limited to a maximum of US$750 million. So far, CSL has spent or committed a total of around A$1.06 billion, all in Australian dollars.
Timing is key here. CSL shares wrapped up Monday’s session off 0.35% at A$124.40, hitting near the bottom of their 52-week span—A$123.88 to A$275.79, according to market data. The buyback, then, is stepping in as shares in one of Australia’s top healthcare names keep slipping.
Late April brought a fresh headache for CSL, as the U.S. Department of Defense scrapped its flu vaccine mandate—ratcheting up pressure on the company’s Seqirus arm. Marc Jocum at Global X ETFs didn’t mince words, warning the Pentagon’s decision “could be the straw that finally breaks the camel’s back.” Vantage Markets’ Hebe Chen put it bluntly: CSL still hasn’t “convincingly found a floor.” Reuters
That May 4 filing wasn’t just a one-off. CSL’s ASX announcements include buyback updates across May 4, May 1, April 30, April 29, April 27, and April 24, putting its capital return plans in front of investors nearly every session.
The buyback is part of a broader overhaul at CSL. Back in October, Reuters said CSL shelved its Seqirus spin-off plan because U.S. flu vaccination rates dropped more than expected. That same report pointed to a sweeping restructure—including roughly 3,000 job losses—paired with reduced forecasts for revenue and earnings growth.
CSL’s first-half figures spell out the market’s caution about the buyback. In February, the company logged total revenue at US$8.3 billion, a 4% dip, with underlying NPATA of US$1.9 billion—off 7%. Reported net profit after tax? US$401 million, plunging 81%. NPATA, or net profit after tax and amortisation, excludes certain non-cash charges. Chief Financial Officer Ken Lim put it plainly: CSL was “clearly not satisfied” with these results.
The risk side hasn’t changed much. CSL still needs its Behring plasma unit to make up for softer vaccine sales, stepped-up generic pressure in iron drugs, and ongoing shifts in U.S. and China policy. Back in February, interim CEO Gordon Naylor called plasma the “greatest opportunity,” but Citi analysts cautioned there’s not much room for mistakes if CSL wants to meet its targets. Reuters
Vaccines remain a battleground with little room to maneuver—government purchasing can swing quickly. In past U.S. bird-flu vaccine supply deals, GSK and Sanofi joined CSL on the winners’ list, underscoring how these public stockpile contracts tend to rotate among just a handful of major players.
CSL isn’t just about flu shots. The annual report outlines CSL Behring’s focus on rare and serious disease treatments, CSL Seqirus handling influenza prevention and pandemic readiness, and CSL Vifor working in iron deficiency and nephrology. Products reach over 100 countries.
For CSL, earnings are the next real test. The company’s financial year wraps up on June 30, with full-year results and a final dividend announcement scheduled for August 18, per the financial calendar. That’s when investors will see if the buyback lines up with any genuine improvement in operations.
